Alnylam Pharmaceuticals sank -6.1% this afternoon, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Alnylam Pharmaceuticals has logged a -11.0% 52 week change, compared to 20.0% for the S&P 500
-
ALNY has an average analyst rating of buy and is -32.45% away from its mean target price of $245.83 per share
-
Its trailing earnings per share (EPS) is $-8.54, which brings its trailing Price to Earnings (P/E) ratio to -19.4. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $-2.51 and its forward P/E ratio is -66.2
-
The current ratio is currently 3.5, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-469215000 and the average free cash flow growth rate is -0.0%
-
Alnylam Pharmaceuticals's revenues have an average growth rate of 0.0% with operating expenses growing at -50.9%. The company's current operating margins stand at -75.7%